menu
    • menu
    [{"orgOrder":0,"company":"Takara Bio","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"BNT211","moa":"CLDN-6","graph1":"Oncology","graph2":"Preclinical","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takara Bio \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Takara Bio \/ BioNTech"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Termination","leadProduct":"Canerpaturev","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Takara Bio \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"NY-ESO-1.siTCR","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Takara Bio \/ Otsuka Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Takara Bio

    Menu

    Takara Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Takara Bio

                            France arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Takara Bio

                            France arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-ESO-1.siTCR

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for NY-ESO-1ã...

                            Details : NY-ESO-1.siTCRTM (development code: TBI-1301), is a TCR gene transfer T-cell therapy (TCR T-cell therapy) being developed for the treatment of synovial sarcoma.

                            Product Name : TBI-1301

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 11, 2022

                            Lead Product(s) : NY-ESO-1.siTCR

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Takara Bio

                            France arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Takara Bio

                            France arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canerpaturev,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co...

                            Details : Takara Bio and Otsuka have plans for pancreatic cancer and other malignancies after the Phase I clinical trial of TBI-1401, however, in consideration of the time required for future development and other factors, two companies have decided to terminate t...

                            Product Name : TBI-1401

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            September 11, 2021

                            Lead Product(s) : Canerpaturev,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Takara Bio

                            France arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Takara Bio

                            France arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNT211

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BioNTech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Takara Bio Enters into a License and Supply Agreement of RetroNectin® with BioNTech Cell & Gene Therapies Gmb...

                            Details : The patented technologies licensed to BioNTech are based on Takara Bio’s proprietary RetroNectin® method, which includes a technology enabling highly efficient gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with hi...

                            Product Name : BNT211

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 21, 2021

                            Lead Product(s) : BNT211

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BioNTech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth